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RA1
CAN THE PUBLIC’S RISK PREFERENCE WHEN WEIGHING A DRUG’S
RISK/BENEFIT BE TRUSTED?
Wilson L, Pelletier D, Motter C, Basu R, Owen M, Kuan RK, Cheng Y
University of California, San Francisco, San Francisco, CA, USA
OBJECTIVES: To measure utility (risk preference) of individuals deciding to take a 
multiple sclerosis (MS) drug given varying risks/beneﬁ ts. METHODS: A computerized 
measure based on ProSPEQT software was developed to measure Standard Gamble
utility. 45 healthy individuals were presented with 9 health states varying MS disease 
severity (mild, moderate, severe) and asked their preferences to remain in that state 
or gamble on taking a drug with varying probabilities of 3 levels of MS improvements
(mild, average, substantial) but also corresponding probabilities of death. Student’s
t-test analyzed affects of gender, age-groups, education, and MS experience on utility. 
RESULTS: Subjects ranged from 16–69 years (mean  40 years) and 44.4% knew
someone with MS. In general, healthy individuals were willing to accept substantial 
risk of death for even mild MS improvements and accepted more risk for severe MS 
and greater disease improvements. The lowest mean score was for mild MS improve-
ment given mild MS (0.082; 95% CI [0.045–0.120]). The highest score was for sub-
stantial MS improvement given severe MS (0.382; 95% CI [0.295–0.469]). Only
education signiﬁ cantly affected utility for mild improvement in mild MS (p  0.03). 
Individuals with bachelor’s degree or less had 7.7% higher score than post-graduates.
CONCLUSIONS: We found it surprising how much risk of death healthy individuals
were willing to accept (8–38%). This is much greater than the 1/1000 actual risk for 
natalizumab in MS treatment, which the FDA removed from the market. MS patients’
voiced preferences helped get that drug back on the market, showing importance
of shared health decision-making. The FDA and physicians might ﬁ nd it difﬁ cult 
to approve or prescribe drugs with 38% risk of death. However, these preferences
indicate healthy individuals may be less risk-averse than the FDA or physicians,
emphasizing the importance of including the public when weighing risks and beneﬁ ts
of drugs.
RA2
RISK OF DIABETES ASSOCIATED WITH THE USE OF ATYPICAL
ANTIPSYCHOTICS IN CHILDREN AND ADOLESCENTS – A TEXAS
MEDICAID STUDY
Nagar SP, Mehta S, Zweifel P, Chen H
University of Houston, Houston, TX, USA
OBJECTIVES: To examine the risk of developing diabetes among children and ado-
lescents who received atypical antipsychotic drug. METHODS: This study is a retro-
spective cohort analysis using 2003–2004 Texas Medicaid claims data. Patients were 
included in the cohort if they met the following criteria: 6 to 18 years of age, new
users of atypical antipsychotics and had not received a diagnosis of diabetes (ICD-9-
CM code: 250.xx) or a prescription claim of an anti-diabetic drug both before and 
one month after the initiation of an antipsychotic treatment. Risk of newly developed
diabetes following antipsychotic treatment was observed during a 12 month follow-up 
period. Kaplan-Meier survival curves and Cox proportional-hazards regression model
were employed to examine the time dependent risk (hazard) of diabetes and hazards 
ratio were obtained. Age, gender, race and exposure to other diabetogenic medications 
were controlled in the analysis. RESULTS: A total of 4096 patients were identiﬁ ed as
new atypical antipsychotic users. The average age of the cohort was 11 years, most
of the patients were male (65%), and Hispanics (36.5%). Cox-proportional hazard 
model analysis revealed no signiﬁ cant association between use of atypical antipsy-
chotic use and risk of diabetes (Hazards Ratio, HR  1.11, 95% CI  0.81–1.53). 
Children in the older age group of 15–18 years, females and Hispanics had higher risk 
of developing diabetes. Concurrent treatments with corticosteroids, beta-blockers,
thiazides and antidepressants were also associated with increased incidence of diabe-
tes. CONCLUSIONS: Our results indicate that there is no increase in the risk of 
developing diabetes in pediatric patients receiving atypical antipsychotics. The discrep-
ancy in the ﬁ ndings between adults and children implies that psychotropic medications
might function differently in pediatric population from adults. It is necessary to com-
prehensively assess the risks associated with common off-label medications, such as 
atypical antipsychotics, in children and adolescents.
RA3
A BAYESIAN DECISION–ANALYTIC ECONOMIC MODEL TO OPTIMIZE
ALLOCATION OF RISK IN PAY–FOR–PERFORMANCE PAYMENT
ARRANGEMENTS
Mallick R1, Hollenbeak C2
1Risk Sharing Solutions, Collegeville, PA, USA, 2Penn State College of Medicine, Hershey, 
PA, USA
OBJECTIVES: Performance-based payment arrangements for innovative drugs seek
to allocate ﬁ nancial risk of interventions between manufacturers and payers. Given
operational challenges in monitoring real-world outcomes, effective risk sharing
mechanisms may require prediction of incremental survival/quality-adjusted life years
(QALYs) conditional on surrogate markers, for example, complete remission (CR) or 
partial remission (PR). In accepting a risk-sharing arrangement that reimburses only
for remitters, payers should minimize the “false-positive” (FP) risk: early remitters 
who subsequently have limited QALYs. Manufacturers should minimize the “false-
negative” (FN) risk: early non-remitters who subsequently have prolonged QALYs. 
A Bayesian decision framework can be used to choose among multiple likelihood 
(predictive) priors to optimize the posterior economic risk trade-off for payers and 
manufacturers. METHODS: A Bayesian decision-analytic, hypothetical data-based, 
cost-effectiveness model was developed. Prior probabilities and QALYs were assigned 
for 6-, 3-, and 1-month survival, as were treatment costs. A plausible prior likelihood 
(predictive) structure represented the (ROC) relationship between the sensitivity and 
speciﬁ city of CR/PR in predicting survival. Expected (posterior) probabilities of sur-
vival, conditional on CR/PR, were generated. At a threshold of $50,000/QALY, the 
cost-effectiveness of the intervention, conditional on achieving CR/PR, and an optimal 
sensitivity-speciﬁ city trade-off was derived. RESULTS: At a hypothetical treatment 
cost of $5,000/month for a 4-month cycle, a minimal FP of 13% (maximum speciﬁ city
of 87%) and a minimal FN of 33% (maximum sensitivity of 67%) emerged as neces-
sary to be accepted by payers and manufacturers respectively to ensure viable risk-
sharing. At higher sensitivity, payer risk did not meet the reimbursement threshold, 
while at higher speciﬁ city, manufacturers would assume excessive ﬁ nancial risk. Other
illustrations will be discussed. CONCLUSIONS: Manufacturers should propose evi-
dence-based payment arrangements that utilize clinical trial data to develop economic
implications of being at various points on the ROC curve in order to optimize the
trade-offs between payer and manufacturer incentives.
RA4
METABOLIC SYNDROME RISK FACTORS FOR NATIVE BORN AND FIRST
GENERATION ADOLESCENTS (12–17) IN THE UNITED STATES
Hufstader MA1, Sias S1, Vaidya V2, White-Means S1
1University of Tennessee Health Science Center, Memphis, TN, USA, 2University of Tennessee, 
Memphis, TN, USA
OBJECTIVES: To contrast the factors that are associated with metabolic syndrome
risk for both adolescents overall and Hispanic adolescents in the U.S. METHODS: At 
risk is deﬁ ned as having three or more of the following: elevated fasting glucose, ele-
vated SBP, elevated DBP, elevated triglycerides, elevated BMI, elevated waist circumfer-
ence, or low HDL. Logistic regression and NHANES 2003–2006 data were used to 
examine the impact on metabolic syndrome risks; gender, race, ethnicity, immigrant 
status, income, insurance, parental education, activity levels, number of school lunches
and breakfasts per week, milk consumption, language preference, and number of 
meals outside the home per week. Adolescents in the United States overall are com-
pared with Hispanic adolescents in the U.S. A signiﬁ cance level of 0.05 was used. 
Weighted sample sizes for Hispanic adolescents and adolescents in the U.S. are 
8,178,714, and 50,837,204. RESULTS: Major differences include the decreased risk
(42%) for adolescent females overall in the U. S., and the increased risk (17%) for
Hispanic females in the U.S. Notably, for those Hispanics that are ﬁ rst generation, 
their risk is increased by 65%. For adolescents overall in the U.S., low or middle
income levels increase risk three times, while low and middle income level Hispanic
adolescents in the U.S. have a risk decrease of 77% and 69% respectively. For every
meal eaten outside the home per week (excluding school meals) the risk increases for 
adolescents in the U.S. by 4% and by 13% for Hispanic adolescents in the U.S.
CONCLUSIONS: These adolescents are at risk for acute cardiovascular endpoints, 
higher medical utilization and expenditure, and lower quality of life. Interventions
should focus on education regarding healthy eating outside the home with limited 
resources. This analysis is the high price of acculturation for Hispanic ﬁ rst generation 
adolescents.
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QUARTERLY ASSESSMENT OF SHORT ACTING b–AGONIST USE 
AS A PREDICTOR OF SUBSEQUENT HEALTH CARE SERVICES USE
FOR ASTHMATICS IN THE U.S.
Blanchette CM1, Silver H1, Petersen H1, Kamble S2, Meddis D3, Gutierrez B3
1Lovelace Respiratory Research Institute, Albuquerque, NM, USA, 2The University of North
Carolina at Charlotte, Charlotte, NC, USA, 3AstraZeneca, Wilmington, DE, USA
OBJECTIVES: Previous research has shown that high utilization of short-acting B-
agonists (SABA) is associated with asthma exacerbations, however annual assessments 
present signiﬁ cant barriers to real-time assessment needed for effective intervention. 
We explored a quarterly assessment of high SABA utilization patterns on subsequent
asthma exacerbations. METHODS: A retrospective cohort study conducted using
PHARMetrics database included health plan members (aged 6–56 years; n  93,604) 
with asthma and two-year continuous enrollment between 7/2003–6/2007, 1 hospi-
talization/emergency department (ED) or 2 outpatient claims of International Classi-
ﬁ cation of Diseases, 9th Revision, Clinical Modiﬁ cation (ICD-9-CM) code 493.XX
and 1 asthma medication claim in each of the two years of observation. Patients with 
COPD and diseases associated with chronic oral steroid use were excluded. SABA 
utilization was converted to canister-count in their ﬁ rst observed quarter and catego-
rized into 0, ½-1, 1½-2, 2. Risk of an asthma exacerbation in the subsequent quarter,
deﬁ ned as an oral steroid claim, hospitalization, or ED visit, was assessed using logistic
regression, controlling for age, sex, region, and several ﬁ rst-quarter severity measures/
comorbidities. RESULTS: The cohort included 33,951 patients aged 6–17 (36%) and 
59653 aged 18–56 (64%) of which 64% had 0 SABA canisters, 18% had ½-1, 9% 
had 1½-2, and 9% had 2. Compared to 0 canisters, higher SABA utilization was 
associated with higher exacerbation risk [½-1 (OR:1.01; CI:0.92–1.12), 1½-2 
